Comparative Pharmacology
Head-to-head clinical analysis: FORTEO versus PARATHAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTEO versus PARATHAR.
FORTEO vs PARATHAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human parathyroid hormone analog (1-34) that stimulates osteoblast activity, increasing bone formation and turnover.
Recombinant human parathyroid hormone (PTH 1-84) that binds to PTH1 receptor, stimulating osteoblast activity and bone formation, increasing bone mineral density.
20 mcg subcutaneously once daily.
50-100 mcg subcutaneously once daily.
None Documented
None Documented
Terminal half-life: approximately 1 hour (subcutaneous administration). Clinically, the short half-life supports once-daily dosing; no accumulation observed with daily dosing.
Terminal half-life: 4-6 hours (prolonged to 10-12 hours in renal impairment; caution in CrCl <30 mL/min).
Renal (metabolites, primarily via glomerular filtration and tubular secretion; ~95% of absorbed dose eliminated in urine within 24 hours). Biliary/fecal: minimal (< 2%).
Renal: 70% unchanged, biliary/fecal: 20% as metabolites, 10% as unchanged drug in feces.
Category C
Category C
Osteoporosis Agent
Osteoporosis Agent